Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

Claire N. Harrison, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Laurent Knoops, MD PhD, Francisco Cervantes, Mark M. Jones, MD, Kang Sun, PhD, Laurence Descamps, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Tiziano Barbui, MD

Blood (2015) 126 (23): 59.

https://doi.org/10.1182/blood.V126.23.59.59

Published: 2015

Journal Articles

Continued Treatment with Ruxolitinib Provides Additional Hematocrit Control and Spleen Volume Responses in Patients with PV Treated in the RESPONSE Study

Jean-Jacques Kiladjian, MD PhD, Tamás Masszi, MD PhD, Mark M. Jones, MD, Brian Gadbaw, MD, Jingjin Li, PhD, Dany Habr, MD, Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD

Blood (2015) 126 (23): 2804.

https://doi.org/10.1182/blood.V126.23.2804.2804

Published: 2015

Journal Articles

Ruxolitinib Efficacy By Hematocrit Control in Patients with Polycythemia Vera: An Analysis of the RESPONSE Trial

Srdan Verstovsek, MD PhD, Jean-Jacques Kiladjian, MD PhD, Ruben Mesa, MD, Mark M Jones, MD, Shui He, PhD, Jingjin Li, PhD, Dany Habr, MD, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 3201.

https://doi.org/10.1182/blood.V124.21.3201.3201

Published: 2014

Journal Articles

The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera: A Randomized, Double-Blind, Double-Dummy, Symptom Study (RELIEF)

Ruben Mesa, MD, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD MB, Pierre Zachee, MD PhD, Mamta Garg, MD FRCP, FRCPath, Roger Lyons, MD, Silwan Chedid, MD, Steffen Koschmieder, MD, Ciro Rinaldi, MD PhD, Jennifer Byrne, MB, ChB, PhD FRCP, FRCPath, Yasmin Hasan, MD, Francesco Passamonti, MD, Srdan Verstovsek, MD PhD, Deborah Hunter, PhD, Mark M Jones, MD, Shui He, PhD, Alex Morozov, MD PhD, Bruno Martino, MD

Blood (2014) 124 (21): 3168.

https://doi.org/10.1182/blood.V124.21.3168.3168

Published: 2014

Journal Articles

Clinical Benefit of Ruxolitinib Treatment after Crossover from Best Available Therapy in Patients with Polycythemia Vera: Analysis of the RESPONSE Trial

Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Martin Griesshammer, MD, Tamas Masszi, MD PhD, Simon Durrant, MD, Francesco Passamonti, MD, Claire N Harrison, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Ruben Mesa, MD, Mark M Jones, MD, Shui He, PhD, Jingjin Li, PhD, Dany Habr, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 3181.

https://doi.org/10.1182/blood.V124.21.3181.3181

Published: 2014

Journal Articles

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

Ruben Mesa, MD, Srdan Verstovsek, MD PhD, Jean-Jacques Kiladjian, MD PhD, Martin Griesshammer, MD, Tamas Masszi, MD PhD, Simon Durrant, MD, Francesco Passamonti, MD, Claire N. Harrison, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Shui He, PhD, Mark M Jones, MD, Shreekant Parasuraman, PhD, Jingjin Li, PhD, Isabelle Côté, MD, Dany Habr, MD, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 709.

https://doi.org/10.1182/blood.V124.21.709.709

Published: 2014

Journal Articles

Efficacy of Ruxolitinib By Baseline Spleen Volume in Patients with Polycythemia Vera Resistant to or Intolerant of Hydroxyurea

Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD, Mark M Jones, MD, Shui He, PhD, Jingjin Li, PhD, Dany Habr, MD, Jean-Jacques Kiladjian, MD PhD

Blood (2014) 124 (21): 1840.

https://doi.org/10.1182/blood.V124.21.1840.1840

Published: 2014

Journal Articles

Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML)

Lia Gore, MD, Margaret E. Macy, M.D., Francoise Mechinaud, MD, Aru Narendran, MD, PhD, Frank Alvaro, MD, Carola A.S. Arndt, MD, Phillip Barnette, MD, Jessica Boklan, MD, Todd Cooper, DO, Laura Martin, MD, W Tcheng, MD, Peter Tarassoff, MD, Mark M Jones, MD, Soheil Meshinchi, MD, PhD, Robert J. Arceci, MD, PhD

Blood (2012) 120 (21): 1517.

https://doi.org/10.1182/blood.V120.21.1517.1517

Published: 2012

Journal Articles

A Post Hoc Landmark Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Xavier Thomas, MD, Christopher Arthur, MD, Jacques Delaunay, MD, Mark M Jones, MD, Erhan Barrak, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 3623.

https://doi.org/10.1182/blood.V120.21.3623.3623

Published: 2012

Journal Articles

Multivariate and Subgroup Analyses of a Multinational Phase III Trial of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Jiri Mayer, M.D., PhD., Prof., Christopher Arthur, MD, Jacques Delaunay, MD, Grzegorz Mazur, MD, PhD, Xavier Thomas, MD, Agnieszka Wierzbowska, MD, PhD, Mark M Jones, MD, Erhan Berrak, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 3618.

https://doi.org/10.1182/blood.V120.21.3618.3618

Published: 2012

Journal Articles

A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS),

Bipin Mistry, Ph.D., Mark M Jones, MD, Peter Kubiak, Ph.D., Guillermo Garcia-Manero, Mark R. Litzow, MD, Ruben A. Mesa, MD, Robert Rifkin, MD, Peter Tarassoff, MD, Ph.D., Jorge E. Cortes

Blood (2011) 118 (21): 3801.

https://doi.org/10.1182/blood.V118.21.3801.3801

Published: 2011

NARROW

Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

Continued Treatment with Ruxolitinib Provides Additional Hematocrit Control and Spleen Volume Responses in Patients with PV Treated in the RESPONSE Study

Ruxolitinib Efficacy By Hematocrit Control in Patients with Polycythemia Vera: An Analysis of the RESPONSE Trial

The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera: A Randomized, Double-Blind, Double-Dummy, Symptom Study (RELIEF)

Clinical Benefit of Ruxolitinib Treatment after Crossover from Best Available Therapy in Patients with Polycythemia Vera: Analysis of the RESPONSE Trial

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

Efficacy of Ruxolitinib By Baseline Spleen Volume in Patients with Polycythemia Vera Resistant to or Intolerant of Hydroxyurea

Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML)

A Post Hoc Landmark Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Multivariate and Subgroup Analyses of a Multinational Phase III Trial of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS),

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only